In 2019, Regeneron and Alnylam entered a broad, multi-product partnership focused on developing and commercializing CNS, ocular, and certain liver RNAi therapeutics. This multi-year collaboration, valued at over $1 Billion, was structured to leverage scientific expertise from each organization. It combines Alnylam's knowledge and experiences with a new class of innovative medicines and emerging global commercial presence in addition to Regeneron's world-leading capabilities in human genetics and industry-leading commercial presence in ophthalmology.
To fully extract the value of these capabilities, this landmark alliance requires each party to deeply contribute to and learn from one another in order to bring meaningful medicines to patients. Given the intimate nature of the collaboration, from inception the alliance leads were tapped as core members of the deal team. By bringing operational and behavioral knowledge of their respective organizations, and case-examples of challenges faced in other partnerships, the alliance professionals were able to provide practical counsel to business development, while incorporating meaningful considerations into the contract.
In this session key strategies highlighted include:
Vin Sharma, CA-AM
Senior Director, Head of Alliance Management
Vin leads alliance management at Alnylam Pharmaceuticals, building on the organization's capability as a world-class leader in partnering. Under Vin's purview, his team manages Alnylam's portfolio of partnerships from drug discovery to commercialization, and across rare, cardiometabolic, hepatic infectious, CNS and ophthalmic diseases. During his tenure, Vin has been a key member of multiple deal teams, kicked-off new partnerships, and has established alliance best practices and processes across and between organizations.
Prior to Alnylam, Vin was most recently at Vertex Pharmaceuticals where he held multiple commercial roles including in global marketing, US marketing, sales, and new product planning. A former consultant, program manager, and case manager Vin leverages his diverse experiences and engagements to strategize, build upon and promote alliance management principles. Vin holds an MBA from MIT Sloan School of Management, an MPH with a focus on organizational behavior from Boston University, and a BS in neuroscience & psychology from Brandeis University.
Jung Hwan Sung, PhD
Senior Director, Strategic Alliances
Jung is a Senior Director of Strategic Alliances at Regeneron. Jung supports strategic collaborations across all stages of alliances and frequently serves on deal teams for major collaborations in the making. Prior to Regeneron, Jung was with the Boston Consulting Group (BCG), where he advised biopharma and medical device companies on topics across corporate development and strategy, due diligence and transaction support, digital innovation, R&D transformation, commercial excellence as well as large-scale/global transformation and post-merger/acquisition integration. Jung is a Ph.D immunologist by training from Harvard University. Jung also worked as a software engineer at a mobile device startup in South Korea, as well as a computational biologist at the Whitehead institute.